Back to mobile site

Citizens Reiterates Market Outperform Rating on Mirum Pharmaceuticals (MIRM)

September 14, 2026 9:43 AM EDT Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $137.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login